Skip to main content

Table 4 Surgery and pathological staging for patients

From: Prognostic significance of lung radiation dose in patients with esophageal cancer treated with neoadjuvant chemoradiotherapy

Characteristics

Overall (n = 123)

Time from NCRT to surgery (weeks), median (IQR)

6.7 (5.4–8.3)

Pathological T stage, n (%)

 pT0

52 (42.3)

 pT1

15 (12.2)

 pT2

19 (15.4)

 pT3

35 (28.5)

 pT4a

2 (1.6)

Pathological N stage, n (%)

 pN0

82 (66.7)

 pN1

24 (19.5)

 pN2

13 (10.6)

 pN3

4 (3.3)

Pathological TNM stage, n (%)

 pT0N0

46 (37.4)

 I

14 (11.4)

 II

33 (26.8)

 III

30 (24.4)

Tumor regression grade, n (%)

 0

46 (37.4)

 1

11 (8.9)

 2

60 (48.8)

 3

6 (4.9)

R0 resection, n (%)

 All location

104 (84.6)

 Upper

18 (14.6)a

 Middle

48 (39.0)a

 Lower

38 (30.9)a

  1. Abbreviations: NCRT neoadjuvant chemoradiotherapy, IQR interquartile range
  2. aLocation specific R0 resection rate: upper (75.0%), middle (81.7%), lower (94.9%)